Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Gross Profit | -15M | 1.9% |
| Cost of Revenue | 15M | 1.9% |
| Operating expense | 53M | 14% |
| Net Income | -50M | 13.9% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 397M | 10.9% |
| Total Liabilities | 93M | 7% |
| Total Equity | 304M | 12.1% |
| Shares Outstanding | 61M | 0% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -48M | 47.7% |
| Cash from investing | 39M | 26.4% |
| Cash from financing | 100,000 | 81.2% |
EPS
Financial Highlights for Pliant Therapeutics in Q4 '24
Gross Profit stood at -15M, marking a -1.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 15M, a 1.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 53M, showing a -14% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -50M, showing a 13.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Pliant Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
